Evolent Health (EVH) Expected to Announce Earnings on Thursday

Key Points

• Evolent Health (NYSE: EVH) is set to release its Q2 2025 earnings results on August 7th, with expectations of $0.10 earnings per share and $459.43 million in revenue.
• Wall Street analysts are generally optimistic, with a consensus rating of "Buy" and a target price averaging $17.93, following multiple rating upgrades.

Evolent Health (NYSE:EVH - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Evolent Health to post earnings of $0.10 per share and revenue of $459.43 million for the quarter. Evolent Health has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a positive return on equity of 3.64% and a negative net margin of 4.54%. The company had revenue of $483.65 million for the quarter, compared to analysts' expectations of $460.15 million. During the same quarter in the prior year, the firm earned $0.34 EPS. The firm's revenue was down 24.4% on a year-over-year basis. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Trading Down 1.6%

Shares of NYSE EVH traded down $0.16 during trading on Monday, hitting $9.82. 595,681 shares of the company were exchanged, compared to its average volume of 2,530,299. The firm has a market capitalization of $1.15 billion, a PE ratio of -7.99 and a beta of 0.82. Evolent Health has a 12-month low of $7.06 and a 12-month high of $33.63. The company has a fifty day moving average price of $9.73 and a 200-day moving average price of $9.66. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.98 and a current ratio of 0.98.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EVH. Needham & Company LLC restated a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. Truist Financial boosted their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Finally, UBS Group boosted their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $17.93.

Hedge Funds Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio acquired a new stake in shares of Evolent Health in the first quarter valued at approximately $47,000. Caxton Associates LLP acquired a new stake in shares of Evolent Health in the first quarter valued at approximately $252,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Evolent Health by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock valued at $1,217,000 after acquiring an additional 3,572 shares during the period. Brighton Jones LLC acquired a new stake in shares of Evolent Health in the fourth quarter valued at approximately $3,927,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock valued at $26,861,000 after acquiring an additional 1,754,520 shares during the period.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.